Abstract
Background:Guselkumab (GUS), a fully human interleukin (IL)-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults with active psoriatic arthritis...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have